Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Single Blind, Placebo Controlled, Single Center Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of Single and Multiple Ascending Doses of Subcutaneously Administered RBD7022 in Participants With Normal or Elevated LDL-c Cholesterol

NCT05912296 is registered in ClinicalTrials.gov with Suzhou Ribo Life Science Co. Ltd. as lead sponsor.

NCT NCT05912296
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05912296 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Single Blind, Placebo Controlled, Single Center Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of Single and Multiple Ascending Doses of Subcutaneously Administered RBD7022 in Participants With Normal or Elevated LDL-c Cholesterol
Lead sponsor
Suzhou Ribo Life Science Co. Ltd.
Phase
Phase 1
Overall status
Completed
Start date
May 30, 2023
Completion date
March 31, 2025
Enrollment
80 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hyperlipemia